BHWM
RYTM icon

Beaird Harris Wealth Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Beaird Harris Wealth Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-49
Closed -$809 – 479
2023
Q2 		$809 Hold
49
– – ﹤0.01% 408
2023
Q1 		$875 Hold
49
– – ﹤0.01% 419
2022
Q4 		$1.43K Hold
49
– – ﹤0.01% 618
2022
Q3 		$1K Hold
49
– – ﹤0.01% 455
2022
Q2 		$0 Hold
49
– – ﹤0.01% 565
2022
Q1 		$1K Hold
49
– – ﹤0.01% 575
2021
Q4 		$0 Buy
+49
New +$550 ﹤0.01% 663

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Beaird Harris Wealth Management's RYTM Position: Q3 2023 in Review

Beaird Harris Wealth Management sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2023, closing a stake of 49 shares — an estimated $809 sold.

Beaird Harris Wealth Management first reported a position in RYTM in Q4 2021 and held it in 7 quarters. The position peaked at $1.43K in Q4 2022. 143 funds tracked by Wall St. Rank hold RYTM as of Q3 2023.

  • Beaird Harris Wealth Management reported no remaining Rhythm Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 49 Rhythm Pharmaceuticals shares in Q3 2023, an estimated $809.
  • Beaird Harris Wealth Management first reported a position in Rhythm Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Beaird Harris Wealth Management's Rhythm Pharmaceuticals position peaked at $1.43K in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2023.

Based on Beaird Harris Wealth Management's 13F filing for Q3 2023, filed 15 Nov 2023.